#clinicaltrials
New pancreatic cancer drug shows major survival gains in Phase 3 study
REDWOOD CITY, California — Revolution Medicines announced positive results from a late-stage clinical trial evaluating its experimental drug daraxonrasib, showing a significant survival benefit for patients with advanced pancreatic cancer who had previously undergone treatment. According to the company, patients receiving the once-daily oral therapy lived a median of 13.2 months, compar
New pancreatic cancer drug shows major survival gains in Phase 3 study
REDWOOD CITY, California — Revolution Medicines announced positive results from a late-stage clinical trial evaluating its experimental drug daraxonrasib, showing a significant survival benefit for patients with advanced pancreatic cancer who had previously undergone treatment. According to the company, patients receiving the once-daily oral therapy lived a median of 13.2 months, compar









